Cefzim

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefzim

Quick Facts

Property Description
Active ingredient Ceftazidime
Form Sterile powder for injection
Pharmacological class Third-generation cephalosporin (Antibiotic)
Common use Combatting serious bacterial infections
Origin Semi-synthetic

What Type of Antibiotic is Cefzim (Ceftazidime)?

Cefzim is a brand name for the prescription-only drug Ceftazidime, which is a powerful, semi-synthetic medicine classified as a beta-Lactam antibiotic. It belongs specifically to the third-generation cephalosporin class, a category of antimicrobials designed for robust action against certain bacterial pathogens that display resistance to older agents. Ceftazidime is used in treating critical, systemic infections. The drug is supplied as a sterile powder for injection, intended for parenteral administration (intravenous or intramuscular), which facilitates its use primarily in hospital settings where rapid, reliable drug levels are necessary.

How is Cefzim Classified and Prepared?

Ceftazidime is classified based on its key structural feature: enhanced stability against the beta-lactamase enzymes that bacteria use to achieve resistance. This structural advantage allows it to retain high activity against numerous Gram-negative bacteria. The medicine is particularly useful in managing infections caused by these organisms, which include the challenging Pseudomonas aeruginosa. Cefzim is a single-active ingredient product, focusing exclusively on the potency of Ceftazidime. Its powder form is a key feature, maximizing its chemical stability until the point of reconstitution and use, which is critical for maintaining the therapeutic viability of this specialized antibiotic.

What is the General Therapeutic Role of Ceftazidime?

The general therapeutic role of Ceftazidime is to rapidly and decisively combat serious bacterial infections where a potent, bactericidal agent is required. Its mechanism of action is fundamentally bactericidal, meaning it directly kills the target bacteria by inhibiting the construction and repair of the bacterial cell wall. A typical use scenario involves its application in treating severe, complicated infections in hospitalized patients, where its efficacy against resistant Gram-negative pathogens provides a significant clinical advantage.

What side effects are possible with Cefzim?

Possible Side Effects and Safety Information

The safety profile of Cefzim (Ceftazidime) is characterized by documented adverse reactions classified by frequency and affected organ system, as detailed in official regulatory prescribing information. The most common effects involve the gastrointestinal system and local administration site reactions.

Frequency and System Classification

Adverse reactions classified as Common (affecting up to 1 in 10 patients) include diarrhea, eosinophilia, thrombocytosis, and phlebitis or pain at the injection site. Transient elevations in liver enzymes, such as ALT and AST, are also commonly reported. Uncommon reactions include nausea, vomiting, abdominal pain, headache, and certain blood cell changes like neutropenia or leukopenia.

Serious Adverse Reactions and Key Constraints

Official labeling highlights the potential for serious adverse reactions. The most severe are related to hypersensitivity, including anaphylactic reactions. Furthermore, the drug carries a warning regarding the potential for Central Nervous System (CNS) toxicity, such as seizures and encephalopathy. These CNS effects are explicitly associated with high drug concentrations resulting from unadjusted dosing in individuals with existing renal impairment (kidney problems). Serious Clostridioides difficile-associated diarrhea (CDAD) is also a documented risk following antibiotic use.

Cefzim is contraindicated in patients with a history of hypersensitivity to ceftazidime, any cephalosporin, or other beta-lactam antibiotics due to the risk of severe allergic reactions. Prolonged use may also lead to superinfection by non-susceptible organisms. The medicine requires close safety consideration regarding pre-existing renal function.

Overdose and Emergency Response

Documented Overdose Presentations and Manifestations

Official regulatory documents define the Ceftazidime overdose profile primarily through the risk of severe neurological manifestations. Overdosage has been formally documented to present with serious central nervous system events including seizure activity, encephalopathy, asterixis, myoclonia, and coma. These severe outcomes constitute the documented clinical manifestations of an acute overdosage.


Population-Specific Risk and Emergency Actions

The most critical factor associated with these serious manifestations is impaired renal function. Overdosage has specifically occurred in patients with renal failure who received unadjusted dosage regimens, thereby defining the critical risk population. When an acute overdosage is suspected, regulatory information mandates specific emergency actions. Patients must be carefully observed and provided supportive treatment. This procedural requirement establishes the need for urgent medical help.

Furthermore, hemodialysis or peritoneal dialysis are procedural steps officially documented to aid in the removal of ceftazidime from the body, particularly in the presence of renal insufficiency. No specific antidote is explicitly documented in the official prescribing information.

Therapeutic Uses of Cefzim

What Cefzim Treats: Main Uses and Benefits

Cefzim (Ceftazidime) is used to manage serious bacterial infections that cause acute, disruptive symptoms. It is applied across domains where additional symptomatic support is needed to target the pathogen and provide relief during critical illness.

The medication is commonly used to help with conditions presenting with systemic or localized discomfort, such as bacterial septicemia, meningitis, severe pneumonia, complicated urinary tract infections, and bone and joint infections. Its use is relevant when symptoms are linked to organ-specific functional stress and require supportive management.

In clinical settings involving acute or unstable symptom patterns, Cefzim is considered relevant in the management of these conditions, especially when infections are driven by resistant pathogens like Pseudomonas aeruginosa. This targeted approach contributes to improved comfort and assists with maintaining functional stability in affected areas.

“Cefzim is considered relevant in contexts involving heightened systemic burden, providing supportive relief when symptoms interfere with routine activities.”

Empirical Support for Febrile Neutropenia

Cefzim is applied in clinical settings that involve acute or unstable symptom patterns, such as the urgent management of febrile neutropenia (fever in immunocompromised patients with a low white blood cell count). This approach is used to address the severe symptom of fever and presumed infection, offering essential therapeutic support that supports the patient during critical phases of maximal vulnerability.

Quick Fact: Relief for Serious Symptoms
Symptom Category: Systemic Fever, Organ Distress, and Profound Malaise
Common Use Context: Acute, complicated infections requiring urgent hospital care
Primary Patient Benefit: Helps ease the overall symptom burden and supports general well-being

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Cefzim?

The use of Cefzim (Ceftazidime) is governed by official regulatory rules that define specific population eligibility and exclusion criteria.

Absolute Exclusions (Contraindications)

Cefzim is strictly contraindicated for individuals with a known hypersensitivity to the drug, to any of its components, or to the cephalosporin class of antibiotics. Furthermore, use is prohibited in patients with a history of a severe allergic reaction, such as anaphylaxis, to any other beta-lactam antibacterial agent, including penicillins or carbapenems.

Populations with Restricted or Conditional Use

Eligibility is limited based on organ function and age. Patients with impaired kidney function have a mandatory restriction, which requires a reduction in the standard total daily dosage. Use in severe hepatic impairment is restricted because official study data are not available. Older adults (over 80 years of age) have a specific daily dose limit due to age-related reduced clearance. Use should also be approached with caution in patients with a history of gastrointestinal diseases, particularly colitis.

Pregnancy and Lactation Status

For pregnant patients, use is conditional; it is only permitted if the treating professional determines that the expected benefit outweighs the potential risks. Use during breastfeeding is generally considered acceptable and compatible, as regulators anticipate no adverse effects on the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official prescribing information documents specific interaction patterns for Cefzim (Ceftazidime) with other medicinal products and laboratory tests.


Drug–Drug Interaction Classifications

  • Avoided Combination: Co-administration with Chloramphenicol is formally advised against due to documented in vitro antagonistic effects. This interaction may compromise the desired bactericidal action of Cefzim.
  • Increased Toxicity Risk: Concurrent use with Aminoglycosides (such as Gentamicin) increases the potential for nephrotoxicity and ototoxicity. Similarly, co-administration with high doses of potent diuretics, including Furosemide, may adversely affect renal function.
  • Pharmacokinetic Clearance: Regulatory studies indicate that the co-administration of Probenecid does not affect the elimination kinetics of Ceftazidime. This confirms that Cefzim is primarily cleared by glomerular filtration and is not susceptible to certain tubular secretion interactions.

Condition-Specific Accumulation

In patients with impaired renal function, the drug’s clearance is reduced, which leads to drug accumulation. This increased systemic exposure poses an elevated risk of neurological sequelae, as stated in the prescribing documents.


Non-Drug Interaction

Cefzim administration may result in a false-positive reaction for glucose in the urine when tested using copper-reduction methods (e.g., CLINITEST®). The use of enzymatic glucose oxidase reactions is recommended to avoid this procedural interference.

Mechanism of Action

Irreversible Blockade of Bacterial Cell Wall Assembly

Cefzim, a beta-Lactam antibiotic, acts by engaging and irreversibly inhibiting Penicillin-Binding Proteins (PBPs), a class of bacterial enzymes (transpeptidases) essential for synthesizing the rigid structure of the peptidoglycan cell wall. This molecular action immediately halts the crucial process of cross-linking the wall's structural components. The resulting structural flaw leads directly to a bactericidal effect.


Interference with Replication and Septum Formation

The drug exhibits high affinity for PBP-3, an enzyme responsible for constructing the septum, the new wall that forms when a bacteria divides. By disrupting the PBP-3 enzyme, Cefzim prevents the pathogen from completing the physical separation of daughter cells, resulting in the failure of replication. This interference with the cell division machinery, coupled with the structural damage, ensures the pathogen population is suppressed, contributing to the drug's bactericidal mechanism.

Dosage and Administration Information

Administration Guidelines for Cefzim (Ceftazidime)

Cefzim is an injectable medicine supplied as a sterile powder that must be reconstituted and diluted prior to use. Administration must occur in a supervised clinical setting by a healthcare professional.


Route and Frequency

Administration Route Standard Adult Dose Range Frequency
Intravenous (IV) Injection or Infusion 500 mg to 2 g Every 8 to 12 hours
Intramuscular (IM) Injection 250 mg to 1 g Every 8 to 12 hours

IV doses are typically administered as a slow bolus injection over 3 to 5 minutes or as a standard infusion over 20 to 30 minutes. Treatment duration is typically 7 to 14 days, guided by clinical progress.


Dose Adjustments and Special Populations

Because Ceftazidime is primarily eliminated by the kidneys, dose reduction or interval extension is required for patients with impaired renal function (creatinine clearance le 50 mL/min). An initial 1 g loading dose may be given, followed by maintenance doses adjusted according to the patient’s estimated creatinine clearance. For example, a 1 g dose should be given every 12 hours for a CrCl between 31 and 50 mL/min.

  • Pediatric patients (1 month to 12 years) receive weight-based dosing, usually 30 to 50 mg/kg up to 6 g per day, divided every 8 hours.
  • Older adults may require dose adjustment due to age-related decline in kidney function; the daily dose should not normally exceed 3 g for those over 80 years of age.
  • Hemodialysis patients require a repeat maintenance dose after each dialysis session.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cefzim

Evidence for Use in Serious Bacterial Infections

Research on Cefzim (Ceftazidime) has primarily centered on its application in treating serious systemic and localized infections, such as those affecting the blood (septicemia), lungs (severe pneumonia), and bones or joints. To evaluate its use, researchers conducted short-term Randomized Controlled Trials (RCTs), where Cefzim was compared against other established antibiotics. Additionally, large-scale observational studies have monitored its use in real-world hospital settings.

These studies used measurement tools related to physical discomfort and systemic or functional imbalance. Researchers monitored the clinical response (whether the patient’s signs of infection resolved) and looked for microbiological clearance (the measurement of target organism elimination). Findings reported in these trials describe patterns observed in how clinical response evolved in the short follow-up period, particularly when the infection was studied for Gram-negative bacteria like Pseudomonas aeruginosa.

Evidence for Use in Empiric Treatment of Febrile Neutropenia

Cefzim was evaluated in research contexts involving fluctuating or unstable symptoms, specifically in the urgent treatment of febrile neutropenia (fever in immunocompromised patients). Multicenter RCTs and prospective cohort studies were conducted to explore its use as an initial treatment when the specific cause of the fever was unknown.

The research examined outcomes reflecting daily functioning or activity level, monitoring the rate at which the fever and other symptoms resolved without the need to switch the initial antibiotic. Studies also monitored infectious mortality in these high-risk populations, with findings describing group patterns under the specific conditions of the trials. Reported outcomes were short-term, typically focusing on measurements of success rates measured within the first one to two weeks of treatment.

What Research Gaps and Uncertainties Remain

The research landscape for Cefzim presents several areas of uncertainty. Evidence quality varies across studies, and the interpretation of findings is continuously challenged by changes in bacterial susceptibility worldwide. The certainty remains low regarding sustained clinical response patterns of Cefzim monotherapy against highly resistant pathogens, which is an increasingly relevant factor in clinical settings. Furthermore, comparative evidence is lacking for Cefzim against the very newest generation of antibiotics.

Key Studies & References

  1. Ceftazidime for Injection, USP - DailyMed (Used for general prescribing and special population context)

Frequently Asked Questions (FAQ)

Common questions about Cefzim (FAQ)

Q: What are the most common stomach side effects people report with Cefzim?

A: Official product information indicates that the most commonly reported gastrointestinal side effect with Cefzim is diarrhea. Other side effects involving the digestive system, such as nausea, vomiting, and abdominal pain, have also been reported, though less frequently.


Q: Is Cefzim safe to use if I have a known allergy to other cephalosporins?

A: Cefzim is strictly contraindicated (prohibited) for individuals who have a known allergy or hypersensitivity to any drug in the cephalosporin class of antibiotics. Regulatory warnings state that using the medication in this situation carries the risk of a severe allergic reaction.


Q: What symptoms indicate that an allergic reaction to Cefzim is becoming serious?

A: Regulatory labeling warns about the potential for serious hypersensitivity reactions, including a severe, life-threatening reaction known as anaphylaxis. A severe allergic reaction requires immediate medical attention, and the treating professional will determine the next steps, including discontinuation.


Q: Are there any long-term effects of taking Cefzim multiple times?

A: Official information states that prolonged use of Cefzim may lead to a superinfection (a new infection caused by organisms the antibiotic does not target). Repeated or long-term courses are generally managed under the supervision of a healthcare professional.


Q: Is Cefzim safe for people who have diabetes?

A: While not directly contraindicated, official labeling notes that Cefzim can cause a false-positive result when testing for glucose in the urine using copper-reduction methods (like CLINITEST®). For accurate results, the official labeling recommends the use of enzymatic glucose oxidase methods to test for urine glucose.


Q: Why is it important to finish the whole course of Cefzim, even if I feel better?

A: Completing the entire prescribed course is essential to fully treat the existing infection. This adherence also helps prevent the remaining bacteria from becoming resistant to the drug and supports the medication's continued effectiveness.


Q: What kind of infections does Cefzim treat in children?

A: In pediatric patients, Cefzim is indicated for the treatment of various serious infections. These indications include conditions such as bacterial meningitis, complicated urinary tract infections, severe hospital-acquired pneumonia, and bone and joint infections.


Q: Why would a doctor choose Cefzim over Amoxicillin for an infection?

A: Cefzim is classified as a third-generation cephalosporin, which gives it a different spectrum of activity compared to older antibiotics like Amoxicillin. It is often chosen for its specific effectiveness against challenging Gram-negative bacteria, including Pseudomonas aeruginosa, which accounts for its specific use in treating certain serious infections.


Q: Can Cefzim cause a metallic taste in the mouth, and is that normal?

A: Changes in taste, which some patients describe as a bad or metallic taste, have been reported as a very rare side effect associated with Cefzim use.


Q: How long does Cefzim stay in your system after you stop taking it?

A: In individuals with normal kidney function, the medication has an elimination half-life of approximately 1.6 to 2 hours. This means that a large portion of the drug is typically cleared from the body by the kidneys and excreted in the urine within about 24 hours of administration.


Q: Can Cefzim make you feel unusually tired or dizzy?

A: Official regulatory labeling reports that dizziness is an uncommon side effect, affecting less than 1% of patients. Headache is also uncommon, but unusual tiredness is not specifically listed among the commonly reported side effects.


Q: Is it possible to develop a rash from Cefzim even after taking it for several days?

A: Yes, hypersensitivity reactions like a rash or itching (pruritus) are documented side effects of Cefzim. As with many antibiotics, allergic reactions can sometimes manifest or progress even after a person has been taking the medication for several days.


Q: Can Cefzim be used to treat ear infections in adults?

A: Cefzim is specifically indicated for the treatment of certain severe ear infections. These include chronic suppurative otitis media and malignant otitis externa, which often require potent, systemic antibiotic therapy.


Q: Does Cefzim affect blood sugar levels?

A: Cefzim does not directly change a patient's blood sugar levels. However, regulatory information states that it can interfere with certain lab tests, potentially causing a false-positive reading for glucose in the urine when tested with specific copper-reduction methods.


Q: Is it normal to feel a bit nauseous when you first start Cefzim?

A: Nausea and vomiting are listed as uncommon side effects of Cefzim, typically affecting less than 1% of patients. Experiencing nausea when first starting the medication is possible, but it is not among the most frequently reported adverse events.


Q: Why do some people say Cefzim makes them feel 'fuzzy' or confused?

A: Official warnings note the potential for Central Nervous System (CNS) toxicity, which can include symptoms like confusion, agitation, or a condition called encephalopathy. This risk is primarily associated with high drug concentrations in the body, which can occur with unadjusted dosing in individuals with reduced kidney function.


Q: Can Cefzim interact with blood thinners like warfarin?

A: Official sources report that Cefzim may have a moderate interaction with blood thinners such as warfarin. This combination may increase the risk of bleeding, and healthcare providers often monitor patients closely when these two medications are used together.


Q: How effective is Cefzim for treating bronchitis or other chest infections?

A: Cefzim is officially indicated for treating lower respiratory tract infections. This includes severe conditions such as pneumonia and specific broncho-pulmonary infections commonly seen in patients with cystic fibrosis.


Q: Are there any special considerations for older adults taking Cefzim?

A: Older adults may require a specific dose adjustment because they are more likely to have reduced kidney function, which affects drug clearance. For this reason, the treating professional may consider a dose adjustment, and the daily dose normally should not exceed 3 grams for patients over 80 years of age.


Q: Does Cefzim work for UTIs (urinary tract infections)?

A: Yes, Cefzim is specifically indicated for the treatment of complicated urinary tract infections. It is typically used in hospital or clinical settings for serious infections caused by susceptible bacteria.


Q: Can Cefzim cause changes in mood or anxiety?

A: Adverse reaction reports associated with Cefzim include changes in consciousness and agitation. These effects relate to the potential for CNS effects, particularly when the concentration of the drug in the body is elevated.


Q: Can Cefzim be safely taken by people with heart conditions?

A: Cefzim is an injectable drug, and the solution contains a small amount of sodium. This is a factor that healthcare providers consider for patients with underlying conditions, such as severe heart failure, or those who are on a restricted sodium diet.


Q: Is Cefzim considered a relatively new or an older, established antibiotic?

A: Cefzim (Ceftazidime) is classified as a third-generation cephalosporin. This is a well-established and essential class of antibiotics that has been used in clinical practice for many serious infections since the 1980s.


Q: Why is Cefzim sometimes prescribed as a one-time, high-dose treatment?

A: Official prescribing information indicates that Cefzim can be used for peri-operative prophylaxis (prevention of infection around the time of surgery). It may be administered as a single dose or short course to prevent potential infection during certain surgical procedures, such as a trans-urethral resection of the prostate (TURP).


Q: Does Cefzim need to be taken with food, or does it matter?

A: Cefzim is supplied as a sterile powder that is reconstituted and administered as an injection, either intravenously (IV) or intramuscularly (IM). As an injectable medication, its administration is not dependent on food intake.


Q: Is it true that Cefzim can change the color of your urine?

A: The drug itself and its prepared solutions can appear light yellow to amber. Since the medicine is excreted primarily through the urine, this color may be noted. However, the regulatory label does not report abnormal changes in urine color as a common side effect.


Q: How does Cefzim target bacteria without harming my own cells?

A: Cefzim is designed to target and inhibit specific enzymes called Penicillin-Binding Proteins (PBPs). These PBPs are critical for building the rigid structure of the bacterial cell wall. Because human cells do not possess a cell wall structure, the drug can selectively kill the bacteria.


Q: How do doctors generally assess the effectiveness of Cefzim during treatment?

A: The effectiveness of Cefzim is typically assessed by monitoring two key factors detailed in clinical studies. These include the patient's clinical response (whether the signs and symptoms of the infection are resolving) and achieving microbiological clearance (eliminating the targeted bacteria).


Q: What is the risk of getting a yeast infection or thrush while on Cefzim?

A: Local infections, including candidiasis (commonly known as thrush or a yeast infection) and vaginitis, are listed as uncommon side effects of Cefzim. Antibiotics can sometimes disturb the body's natural balance of organisms, which may allow yeast to overgrow.

How should Cefzim be stored and disposed of?

How to Store and Dispose of Cefzim

Official regulatory guidance outlines specific requirements for storing and disposing of Cefzim to ensure stability and safety.

Storage Requirements

Condition Requirement
Temperature Store below 25 C (controlled room temperature).
Protection Keep the container tightly closed and protect the medicine from light, moisture, and excessive heat.
Packaging Keep the medication in its original container until use.

Stability and Handling

Liquid or suspended forms of Cefzim must be handled according to strict in-use stability limits; for example, unused reconstituted suspension must be discarded after 14 days. All forms must be kept out of the reach of children.

Disposal Instructions

Do not dispose of Cefzim by flushing it down a toilet or pouring it into a drain. Unused or expired medication must be discarded properly, typically through a drug take-back program or at a hazardous or special waste collection point as mandated by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefzim found in:

A-Z Index: